Mucosis B.V. Signs Research and License Option Agreement With Crucell N.V. (CRXL)
10/8/2012 10:44:12 AM
More...
|
CLC bio Delivers Specialized Antibody Engineering and Selection Software for Crucell N.V. (CRXL)
6/8/2012 9:33:51 AM
More...
|
ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development
4/24/2012 9:54:26 AM
More...
|
Judgment Issued in Crucell N.V. (CRXL) Buy-Out Proceedings
2/28/2012 9:02:25 AM
More...
|
Crucell N.V. (CRXL) Release: Promising Results of Novel Combination Vaccine
1/5/2012 11:09:37 AM
More...
|
Crucell N.V. (CRXL) Discovers Important New Antibody Against Influenza A
7/8/2011 9:28:26 AM
More...
|
Isconova Enters into Adjuvant License Agreement with Crucell N.V. (CRXL)
6/9/2011 9:25:39 AM
More...
|
Crucell N.V. (CRXL), GlaxoSmithKline (GSK) And PATH MVI Partner to Develop Second-Generation Vaccine Against Malaria
6/7/2011 7:54:15 AM
More...
|
Crucell N.V. (CRXL) Intends to Delist Ordinary Shares on NYSE Euronext
3/15/2011 8:10:01 AM
More...
|
Johnson & Johnson (JNJ) Acquires 98.89% of Crucell N.V. (CRXL) Shares
3/9/2011 6:45:08 AM
More...
|
|